Harnessing endogenous opioids for pain relief: Fantasy vs reality

Alan R. Gintzler, PhD; Nai-Jiang Liu, MD, PhD

doi:10.5055/jom.2020.0552

Authors

Alan R. Gintzler, PhD
Nai-Jiang Liu, MD, PhD

DOI:

https://doi.org/10.5055/jom.2020.0552

Keywords:

endogenous opioids, clinical pain control, opioid analgesic tolerance, drug targets

Abstract

Objective: To review evidence demonstrating efficacy and feasibility of harnessing the activity of endogenous opioid analgesic systems for pain management.

Methods: The authors sought to summarize a wealth of data that establish proof of concept that the analgesic activity of endogenous opioids can be exploited to clinically benefit from the enormous pain-relieving abilities of these peptides without contributing to the current crisis of death by synthetic opioid overdose.

Results: There is a plethora of studies demonstrating that not only can endogenous opioids mediate placebo-induced antinociception but they are also active in modulating clinical pain. Earlier studies convincingly demonstrate the effectiveness of psychological strategies to coopt endogenous opioid analgesic systems to produce pain relief. The challenge is to define pharmacological targets for activating endogenous opioid analgesia reliably in a clinical setting. Based on insights gleaned from mechanisms underlying the ebb and flow of analgesic responsiveness to the spinal application of endomorphin 2, multiple signaling proteins were identified that activate endogenous spinal opioid analgesia. Notably, this was achieved in the absence of any exogenous synthetic opioid.

Conclusions: Utilization of drugs that harness endogenous opioid antinociception in accordance with varying physiological states represents a novel approach for effective pain management while mitigating the present epidemic of death by synthetic opioid overdose.

Author Biographies

Alan R. Gintzler, PhD

Department of Obstetrics and Gynecology, State University of New York, Downstate Medical Center, Brooklyn, New York

Nai-Jiang Liu, MD, PhD

Department of Obstetrics and Gynecology, State University of New York, Downstate Medical Center, Brooklyn, New York

References

Baliki MN, Geha PY, Apkarian AV, et al.: Beyond feeling: Chronic pain hurts the brain, disrupting the default-mode network dynamics. J Neurosci. 2008; 28: 1398-1403.

Rodriguez-Raecke R, Niemeier A, Ihle K, et al.: Brain gray matter decrease in chronic pain is the consequence and not the cause of pain. J Neurosci. 2009; 29: 13746-13750.

Apkarian AV, Sosa Y, Sonty S, et al.: Chronic back pain is associated with decreased prefrontal and thalamic gray matter density. J Neurosci. 2004; 24: 10410-10415.

Nicholson B, Verma S: Comorbidities in chronic neuropathic pain. Pain Med. 2004; 5(Suppl 1): S9-S27.

Apkarian AV, Sosa Y, Krauss BR, et al.: Chronic pain patients are impaired on an emotional decision-making task. Pain. 2004; 108: 129-136.

Schwartz N, Temkin P, Jurado S, et al.: Chronic pain. Decreased motivation during chronic pain requires long-term depression in the nucleus accumbens. Science. 2014; 345: 535-542.

Lord JA, Waterfield AA, Hughes J, et al.: Endogenous opioid peptides: multiple agonists and receptors. Nature (Lond). 1977; 267: 495-499.

Chavkin C, James IF, Goldstein A: Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science. 1982; 215: 413-415.

Crine P, Benjannet S, Seidah NG, et al.: In vitro biosynthesis of beta-endorphin in pituitary glands. Proc Natl Acad Sci U S A. 1977; 74: 1403-1406.

Crine P, Benjannet S, Seidah NG, et al.: In vitro biosynthesis of beta-endorphin, gamma-lipoprotein, and beta-lipotropin by the pars intermedia of beef pituitary glands. Proc Natl Acad Sci U S A. 1977; 74: 4276-4280.

Zadina JE, Hackler L, Ge LJ, et al.: A potent and selective endogenous agonist for the mu-opiate receptor [see comments]. Nature. 1997; 386: 499-502.

Levine JD, Gordon NC, Fields HL: The mechanism of placebo analgesia. Lancet. 1978; 2: 654-657.

Levine JD, Gordon NC, Jones RT, et al.: The narcotic antagonist naloxone enhances clinical pain. Nature. 1978; 272: 826-827.

Zubieta JK, Bueller JA, Jackson LR, et al.: Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. J Neurosci. 2005; 25: 7754-7762.

Corder G, Doolen S, Donahue RR, et al.: Constitutive mu-opioid receptor activity leads to long-term endogenous analgesia and dependence. Science. 2013; 341: 1394-1399.

Taylor JJ, Borckardt JJ, George MS: Endogenous opioids mediate left dorsolateral prefrontal cortex rTMS-induced analgesia. Pain. 2012; 153: 1219-1225.

Petrovic P, Kalso E, Petersson KM, et al.: Placebo and opioid analgesia–Imaging a shared neuronal network. Science. 2002; 295: 1737-1740,

Amanzio M, Benedetti F: Neuropharmacological dissection of placebo analgesia: Expectation-activated opioid systems versus conditioning-activated specific subsystems. J Neurosci. 1999; 19: 484-494.

Benedetti F, Arduino C, Amanzio M: Somatotopic activation of opioid systems by target-directed expectations of analgesia. J Neurosci. 1999; 19: 3639-3648.

Liu NJ, von Gizycki H, Gintzler AR: Sexually dimorphic recruitment of spinal opioid analgesic pathways by the spinal application of morphine. J Pharmacol Exp Ther. 2007; 322: 654-660.

Liu NJ, Gintzler AR: Spinal endomorphin 2 antinociception and the mechanisms that produce it are both sex- and stage of estrus cycle-dependent in rats. J Pain. 2013; 14(11): 1522-1530.

Liu NJ, Murugaiyan V, Storman EM, et al.: Plasticity of signaling by spinal estrogen receptor alpha, kappa-opioid receptor and mGluRs over the rat reproductive cycle regulates spinal endomorphin 2 antinociception: Relevance of endogenous biased agonism. J Neurosci. 2017; 37: 11181-11191.

Liu NJ, Murugaiyan V, Storman EM, et al.: Estrogens synthesized and acting within a spinal oligomer suppress spinal endomorphin 2 antinociception: Ebb and flow over the rat reproductive cycle. Pain. 2017; 158: 1903-1914.

Boulware MI, Weick JP, Becklund BR, et al.: Estradiol activates group I and II metabotropic glutamate receptor signaling, leading to opposing influences on cAMP response element-binding protein. J Neurosci. 2005; 25: 5066-5078.

Timmer KM, Steketee JD: Examination of a role for metabotropic glutamate receptor 5 in the medial prefrontal cortex in cocaine sensitization in rats. Psychopharmacology (Berl). 2012; 221: 91-100.

Masu M, Tanabe Y, Tsuchida K, et al.: Sequence and expression of a metabotropic glutamate receptor. Nature. 1991; 349: 760-765.

Aramori I, Nakanishi S: Signal transduction and pharmacological characteristics of a metabotropic glutamate receptor, mGluR1, in transfected CHO cells. Neuron. 1992; 8: 757-765.

Miyashita T, Kubo Y: Extracellular Ca2 + sensitivity of mGlu-R1alpha induces an increase in the basal cAMP level by direct coupling with Gs protein in transfected CHO cells. Receptors Channels. 2000; 7:77-91.

Akam EC, Carruthers AM, Nahorski SR, et al.: Pharmacological characterization of type 1alpha metabotropic glutamate receptor-stimulated [35S]-GTPgammaS binding. Br J Pharmacol. 1997; 121: 1203-1209.

Sharon D, Vorobiov D, Dascal N: Positive and negative coupling of the metabotropic glutamate receptors to a G proteinactivated K + channel, GIRK, in Xenopus oocytes. J Gen Physiol. 1997; 109:477-490.

Berkowitz BA, Ngai SH, Finck AD: Nitrous oxide “analgesia”: resemblance to opiate action. Science. 1976; 194: 967-968.

Goldstein A, Pryor GT, Otis LS, et al.: On the role of endogenous opioid peptides: Failure of naloxone to influence shock escape threshold in the rat. Life Sci. 1976; 18: 599-604.

El-Sobky A, Dostrovsky JO, Wall PD: Lack of effect of naloxone on pain perception in humans. Nature. 1976; 263: 783-784.

Grevert P, Goldstein A: Effects of naloxone on experimentally induced ischemic pain and on mood in human subjects. Proc Natl Acad Sci U S A. 1977; 74: 1291-1294.

Kajii TS, Okamoto T, Yura S, et al.: Elevated levels of betaendorphin in temporomandibular joint synovial lavage fluid of patients with closed lock. J Orofac Pain. 2005; 19: 41-46.

Petraschka M, Li S, Gilbert TL, et al.: The absence of endogenous beta-endorphin selectively blocks phosphorylation and desensitization of mu opioid receptors following partial sciatic nerve ligation. Neuroscience. 2007; 146: 1795-1807.

Niikura K, Narita M, Butelman ER, et al.: Neuropathic and chronic pain stimuli downregulate central mu-opioid and dopaminergic transmission. Trends Pharmacol Sci. 2010; 31: 299-305.

Clemente JT, Parada CA, Veiga MC, et al.: Sexual dimorphism in the antinociception mediated by kappa opioid receptors in the rat temporomandibular joint. Neurosci Lett. 2004; 372: 250-255.

Blenk KH, Habler HJ, Janig W: Neomycin and gadolinium applied to an L5 spinal nerve lesion prevent mechanical allodynia-like behaviour in rats. Pain. 1997; 70:155-165.

Ringkamp M, Eschenfelder S, Grethel EJ, et al.: Lumbar sympathectomy failed to reverse mechanical allodynia- and hyperalgesia-like behavior in rats with L5 spinal nerve injury. Pain. 1999; 79: 143-153.

Abbadie C, Gultekin SH, Pasternak GW: Immunohistochemical localization of the carboxy terminus of the novel mu opioid receptor splice variant MOR-1C within the human spinal cord. Neuroreport. 2000; 11: 1953-1957.

Liu NJ, Storman EM, Gintzler AR: Pharmacological modulation of endogenous opioid activity to attenuate neuropathic pain in rats. J Pain. 2019; 20: 235-243.

Hassan S, Muere A, Einstein G: Ovarian hormones and chronic pain: A comprehensive review. Pain. 2014; 155: 2448-2460.